Calvin G, Chasseaud L F, Down W H, Ballard S A, Hawkins D R
Toxicol Lett. 1983 Sep;18(3):351-7. doi: 10.1016/0378-4274(83)90117-0.
Oral doses (100 mg/kg/day) of a 14C-labelled branched-chain alkylpolyethoxylate [( C5H11]2CH14CH2O[CH2CH2O]6H; abbreviated [14C]A12E6) were extensively absorbed from the gastrointestinal tract of rats. During a multiple dosing regime, a proportion of 14C equivalent to one daily dose was excreted each day. This 14C was excreted in urine and faeces in equal proportions; less than 1% of the dose was expired as 14CO2. Almost all the faecal 14C came from the bile and had undergone enterohepatic circulation. After cutaneous application of [14C]A12E6 to rats (8 mg, 333 micrograms/cm2) under occluded conditions, about 25% of the dose was absorbed, mainly during the first 12 h. After dosing by both routes, the A12E6 was biotransformed to several metabolites that were more polar than the parent compound. Less than 15% of the dose was excreted unchanged.
给大鼠口服14C标记的支链烷基聚乙氧基化物([C5H11]2CH14CH2O[CH2CH2O]6H;缩写为[14C]A12E6)剂量为100毫克/千克/天,其从大鼠胃肠道被大量吸收。在多次给药方案期间,相当于一日剂量的一部分14C每天被排泄。这部分14C以相等比例经尿液和粪便排泄;不到1%的剂量以14CO2形式呼出。几乎所有粪便中的14C都来自胆汁并经历了肠肝循环。在封闭条件下给大鼠经皮施用[14C]A12E6(8毫克,333微克/平方厘米)后,约25%的剂量被吸收,主要在最初12小时内。经两种途径给药后,A12E6被生物转化为几种比母体化合物极性更强的代谢物。不到15%的剂量以原形排泄。